Ionis Pharmaceuticals (IONS) Gains from Investment Securities (2009 - 2026)

Ionis Pharmaceuticals' Gains from Investment Securities history runs 17 years deep, the most recent figure standing at $22.6 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 5745.75% year-over-year to $22.6 million; the TTM figure through Mar 2026 stood at $109.9 million (up 4123.5% YoY), while the FY2025 annual figure was $7.7 million, down 47.68% from the prior year.
• Gains from Investment Securities was $22.6 million for Q1 2026 at Ionis Pharmaceuticals, down from $87.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $87.6 million in Q4 2025 to a low of -$7.9 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged $6.1 million across 5 years, with a median of $10000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities plunged 10276.47% in 2023, then surged 27275.0% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at -$5.2 million in 2022, then surged by 127.44% to $1.4 million in 2023, then sank by 77.61% to $320000.0 in 2024, then soared by 27275.0% to $87.6 million in 2025, then plunged by 74.22% to $22.6 million in 2026.
• The last three Gains from Investment Securities figures came in at $22.6 million (Q1 2026), $87.6 million (Q4 2025), and -$7.9 million (Q3 2025), per Business Quant data.